03 Oct 2026, 15:02 IST
Emcure Pharmaceuticals Limited
Motilal Oswal (MOFSL) · Buy
The report cites Emcure as expected to deliver 21%/32% YoY growth in EBITDA/PAT due to superior execution, and lists it as one of the report's top ideas.
From HEALTHCARE MOFSL PR PG024, written by Motilal Oswal (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.